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Summary
Objective: To compare the clinical effects of laterally wedged insoles and neutrally wedged insoles (used as control) in patients with medial
femoro-tibial knee osteoarthritis (OA).
Design: 6-month prospective randomized controlled study. Patients: outpatients with painful medial femoro-tibial knee OA.
Outcome measures: patient’s overall assessment of disease activity (5 grade scale), WOMAC index subscales and concomitant treatments.
Statistical analysis: Performed as an intention-to-treat analysis. Main criterion: improvement in the patient’s assessment of activity (defined
as a reduction of 1 grade or more at month 6 compared to baseline, and no intraarticular injection or lavage during the study). Secondary
criteria for assessment: (a) improvement in the patient’s assessment of activity at months 1 and 3 compared to baseline, (b) improvement
in the WOMAC subscales at months 1, 3 and 6, compared to baseline (defined as an improvement of at least 30%, and no intrarticular
injection or lavage during the study) and (c) concomitant therapies (analgesics and NSAIDs).
Results: The baseline characteristics of the 156 recruited patients (41 males, 115 females, mean age 64.8 years) were not different in the
two treatment groups. At months 1, 3 and 6 the percentages of patients with improvement in assessment of disease activity, in WOMAC pain,
joint stiffness, and physical functioning subscales were similar in the two groups. The number of days with NSAIDs intake during the previous
3 months was decreased at month 6 compared with baseline in the group furnished with laterally wedged insoles (14.1 days±28 vs 9.9
days±27, P=0.04, Wilcoxon paired test), while it remained unchanged in the other group (15.5 days±24 vs 15±28, P=0.56). Compliance
and tolerance were satisfactory. Compliance was different between the two groups at month 6, with a greater frequency of patients who wore
insoles permanently in the laterally wedged insole group than in the other group (87.8% vs 74.3%; P=0.032).
Conclusion: This study failed to demonstrate a relevant short-term symptomatic effect of laterally-wedged insoles in medial femoro-tibial OA.
However, the decrease in NSAIDs consumption together with better compliance in the treated group are in favor of a beneficial effect of
laterally-wedged insoles in medial femoro-tibial OA. © 2001 OsteoArthritis Research Society International
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Knee osteoarthritis (OA) is a common condition in which
prevalence increases with age. Management includes
pharmacological treatment, i.e., nonsteroid inflammatory
drugs (NSAIDs), analgesics, intraarticular injections of
corticosteroids or other compounds, symptomatic slow act-
ing drugs, and surgery, such as osteotomy and
arthroplasty1–3. Nonpharmacological and nonsurgical man-
agement, such as patient education, physical therapy,738weight management in overweight patients, and orthoses
and assistive devices1–3 are strongly recommended.
Some factors suggest that laterally elevated wedged
insoles might be useful in the treatment of medial femoro-
tibial knee OA. The biomechanical effects of laterally
wedged insoles on knee OA have been evaluated. The
mechanical axis of the lower limb approaches a more
upright position, with decreased loading on the medial
compartment of the knee joint and the tensile force of the
lateral side4. Moreover, the lateral thrust at the knee after
heel strike is reduced with the use of valgus insoles5. The
potential clinical benefit of such insoles can be to improve
symptoms in painful knee OA patients, to prevent long-term
structural deterioration, or both. To our knowledge, the
structural effect of such treatment has never been evalu-
ated. The symptomatic effect has been evaluated in various
studies, all concluding that there is a short-term beneficial
effect5–7. However, all these studies were of open design,
and hence the improvement observed might be due to the
Osteoarthritis and Cartilage Vol. 9, No. 8 739treatment, to the natural history of the disease, and/or to a
placebo effect.
To address this question, a prospective randomized
controlled study, comparing the symptomatic effects of
laterally wedged insoles and neutrally wedged insoles
(used as control), in patients with medial femoro-tibial knee
OA, was undertaken.Material and methods
STUDY DESIGN
This multicenter (three centers), prospective randomized
controlled study was conducted in order to compare the
effects of laterally elevated (valgus) and neutrally wedged
insoles (control), in patients with medial compartment
femoro-tibial knee OA. The study protocol was approved by
the local ethics committee (Hoˆpital Cochin, Paris, France).INCLUSION AND EXCLUSION CRITERIA
Outpatients visiting a rheumatologist and fulfilling the
American College of Rheumatology criteria for knee OA8
were enrolled in the study, after written informed consent
was obtained. The patients were told that the study aimed
to compare two kinds of insoles, but not that one was
presumed to be of greater efficacy than the other. This is
not a full informed consent, but this approach was consid-
ered by the investigators as ethical since it as been
suggested that neutrally wedged insoles might relieve
some symptoms through absorbing impact loading2.
Moreover, this approach was approved by the Ethical
Review Board member. Other inclusion criteria were age
18 or older, pain on a daily basis for at least 1 month during
the last 3 months, pain of at least 30 (100 visual analog
scale) after physical activities during the previous 2 days,
predominance of pain in the medial part of the knee (this
information was obtained by interviewing the patients),
evidence of medial femorotibial OA on plain anteroposterior
X-rays (Kellgren and Lawrence stage ≥2).
Exclusion criteria were functional class of IV
(Steinbrocker), greater or similar reduction in lateral than
medial femorotibial joint space width on plain antero-
posterior X-rays, secondary knee OA9, hip OA, hallux
rigidus, valgus deformity of the midfoot, other symptomatic
deformity of the foot, advanced arthropathy of the hindfoot,
any disease treated with insoles within the past 6 months,
previous ankle arthrodesis, tibial osteotomy within the pre-
vious 5 years, knee joint lavage within the previous
3 months, intraarticular corticosteroid injection within the
previous month, changes in drug treatment for OA within
the previous week.STUDY COURSE
Each patient was recruited by a rheumatologist (one in
each center). The chiropodist (PK) then confirmed the
inclusion and randomized the patient. Symptomatic efficacy
was evaluated using standardized questionnaires mailed to
the patient. Any missing data were collected from the
patient by a research nurse, unaware of the randomization,
by telephone. Tolerability and compliance were also evalu-
ated using standardized questionnaires mailed to the
patient. The amount of concomitant treatment required by
the patient was obtained by the research nurse through atelephone conservation with the patient. Follow-up evalu-
ations were made at months 1, 3, and 6. During the
follow-up, the patients were treated either by their general
practitioner or their rheumatologist, who indicated any
concomitant therapy (analgesics, NSAIDs, intraarticular
injection, etc.).BASELINE EVALUATION
Age, gender, body mass index, Steinbrocker functional
class, pain, past history of knee OA and treatment were
noted.
An anteroposterior weight-bearing standing radiograph
of the knee joints (tube to film distance 100 cm, X-ray
beam centered on joint space and inclined parallel to the
tibial plateau, joint fully extended), and a radiograph of
the femoropatellar joints were made. The Kellgren and
Lawrence (KL) grade10 and the joint space width (using a
clear plastic ruler graduated in half millimeters) of the
medial femorotibial joint were determined. The presence of
OA in homolateral femoropatellar and/or lateral femoro-
tibial joints and in contralateral femoropatellar and/or
femorotibial joints was noted.OUTCOME MEASURES
The patient’s overall assessment of disease activity
during the previous 2 days (0–4 grade scale; none, mild,
moderate, severe, very severe), the Western Ontario and
McMaster Universities (WOMAC) index11, were obtained at
baseline and at months 1, 3, and 6. At baseline and at the
end of the 6 months of the study, the patients were asked
how many days during the previous 3 months he/she
needed concomitant treatment (analgesics, NSAIDs)
because of a painful condition related to his/her knee OA.
Compliance and tolerance were evaluated at months 3
and 6. The patients were asked whether they wore continu-
ously, intermittently, or did not wear insoles. Additionally,
they evaluated tolerance on a 5-grade scale (no discomfort,
mild, moderate, severe, very severe discomfort).TREATMENT
Patients were randomly assigned to one of two groups:
bilateral laterally elevated (valgus) and bilateral neutrally
wedged insoles (Fig. 1). Insoles were made of Ledos
material (Socie´te´ Franc¸aise d’Orthopodie, Paris, France),
mounted on a leather strip. The Ledos material is made of
pure rubber with cork powder, and has a great capacity to
absorb impact loading. The laterally elevated insoles were
individually modeled, with elevation depending on static
pedometer evaluation, but without any biomechanical
evaluation during walking.STATISTICAL ANALYSIS
Analysis was made using an intention-to-treat approach.
The main criterion for assessment of efficacy was chosen
prior to the study and defined as an improvement in the
patient’s overall assessment of disease activity at month 6
compared with baseline. Improvement was defined as a
reduction of 1 grade or more from baseline, and no corti-
costeroid or hyaluronate intraarticular injection or articular
lavage during the follow-up. The presence or not of
740 J. F. Maillefert et al.: Insoles in medial knee osteoarthritisFig. 1. (a) The neutrally and (b) laterally wedged insoles.improvement was compared between the two groups using
Fisher’s exact test.
A difference of 20% between the two groups in the
percentages of patients with an improvement in the
patient’s overall assessment was considered as clinically
relevant. A sample size of 70 patients for each group
was required to detect such a 20% difference, with a
significance level of 95% and a power of 80%.
The baseline characteristics of patients were compared
between the groups with and without an improvement in the
patient’s overall assessment of disease activity at month 6,
using Fisher’s exact test, the Chi-2 test, and ANOVA (after
homogeneity of variances was checked using Levene’s
test). The evaluated variables were as follows: age, gender,
body mass index, Steinbrocker functional class, pain,
patient’s overall assessment of disease activity, WOMAC
subscales, Kellgren and Lawrence radiographic stage, joint
space width, presence of a homolateral femoropatellar
OA, a homolateral lateral femorotibial OA, a contralateral
femoropatellar, medial and lateral femorotibial OA, mean
analgesics and NSAIDs intake during the previous
3 months, treatment with ‘disease modifying drugs’ (yes
or no). A multivariate analysis was then performed. The
dependent variable was the presence or not of an improve-
ment in the patient’s assessment of disease activity. The
independent variables were the insole group, and the
variables which were related with a P value less than 0.05
to the presence or not of an improvement on univariate
analysis.
As a secondary analysis, improvement or not in the
patient’s overall assessment of disease activity at months 1
and 3, compared to baseline, were compared between thetwo groups using Fisher’s exact test. In addition, improve-
ment or not in the WOMAC index subscales at months
1, 3 and 6 was compared between the two groups using
Fisher’s exact test. Improvement in the WOMAC index
subscales was defined as a decrease of ≥30% compared
with baseline, and no corticosteroid or hyaluronate intra-
articular injections, or joint lavage during the follow-up.
The other secondary outcome measure was evaluation
of concomitant therapies. The need for intraarticular injec-
tion or joint lavage during the follow-up was compared
between the two treatment groups using Fisher’s exact
test. The number of days with analgesics and NSAIDs
intake during the previous 3 months were compared with
baseline using Wilcoxon’s paired-test.
Finally, compliance at months 3 and 6 was evaluated
and compared between the groups using the Chi-square
test.Results
One hundred and fifty six patients (41 males, 115
females, mean age 64.8 years±10.4 S.D.) were included.
Figure 2 summarizes the study course. After randomiz-
ation, patients were assigned to neutrally wedged or to
laterally wedged insoles (74 and 82 patients respectively).
The baseline characteristics of patients are shown in Table
I. One patient was lost to follow-up after the 1-month, and
one after the 3 month evaluations. Sudden death occurred
in two patients after the 3-month evaluation. One patient
underwent total arthroplasty of the evaluated knee after the
3-month visit. Four patients decided to withdraw from the
study after the 3-month evaluation due to intolerance (one
patient), inefficacy (two patients), personal reasons (one
patient). In all these patients, the results of the last
evaluation were taken into account as final results.
The patient’s overall assessments of disease activity are
shown in Table II. At month 6 the assessment was
improved in 44 patients, seven of whom received intra-
articular injection or articular lavage during the follow-up.
Consequently, the patient’s assessment was considered as
improved in 37 patients, including 17/74 patients (23%) in
the neutrally wedged insole group and in 20/82 patients
(24%) in the laterally wedged insole group (P=0.85).
Similar results were obtained at months 1 and 3. At month
1, the assessment was considered improved in 19 patients
(26%) in the neutrally wedged insole group and in 18
patients (22%) in the laterally wedged insole group
(P=0.71). At month 3 the assessment was considered
improved in 18 patients (24%) in the neutrally wedged
insole group and in 20 patients (24%) in the laterally
wedged insole group (P=1).
The only variable related to the presence or not of an
improvement of the patient’s overall assessment of disease
activity at month 6 was the baseline patient’s assessment
of disease activity (P<0.001). The greater the baseline
assessment, the higher the percentage of improved
patients: an improvement was observed in none of the
eight patients (0%), 11 of the 76 patients (15%), 23 of the
66 patients (35%), and three of the six patients (50%) with
a baseline overall assessment of I, II, III and IV, respect-
ively. On multivariate analysis, the baseline patient’s
assessment of disease activity was again related to the
presence of an improvement (P=0.001), but the insole
group was not (P=0.9).
The WOMAC index scores are shown in Table II. At
month 6, the WOMAC pain subscale was improved in
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not qualified = 0
qualified = 82
Arthroplasty of the evaluated knee = 1
Sudden death = 1
Lost to follow-up = 1
Inefficacy = 1
Completed treatment = 78
Neutrally-wedged insole group
not qualified = 0
qualified = 74
Sudden death = 1
Lost to follow-up = 1
Intolerance = 1
Inefficacy = 1
Personal reasons = 1
Completed treatment = 69
Randomized patients
(n = 156)
Not eligible for inclusion: n = 18
Patient's refusal: n = 8
Enrolled patients
(n = 182)
Fig. 2. Course of the 6-month randomized trial.16/74 patients (22%) and in 16/82 patients (20%) in the
neutrally and the laterally wedged insole groups, respect-
ively (P=0.84). The WOMAC joint stiffness subscale was
improved in 19 (26%) and in 16 patients (20%) in the
neutrally and the laterally wedged insole groups, respect-
ively (P=0.44). The WOMAC physical functioning subscale
was improved in 10 patients (14%) and in 10 patients (12%)
in the neutrally and the laterally wedged insole groups,
respectively (P=0.82). Similar results were obtained at
months 1 and 3.
Twenty-two patients were treated with corticosteroids
(13 patients) or hyaluronate (six patients), intraarticular
injections, or articular lavage (three patients) during the
follow-up. Among these, 13 were in the neutrally wedgedinsole group and nine in the laterally wedged insole group
(P=0.26).
The need for concomitant treatment during the study is
shown in Table III. At baseline, there was no difference
between the two groups. At month 6, there was a statisti-
cally significant reduction in NSAIDs intake and a trend
toward a reduction in analgesic intake in the laterally-
wedged insole group, while in the other group the con-
sumption of analgesics and NSAIDs remained unchanged,
suggesting a symptomatic drug-sparring effect of the later-
ally wedged insoles.
Compliance and tolerance were satisfactory. At endpoint,
127 patients wore insoles permanently, 16 intermittently,
and eight no longer wore insoles (data missing for five
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Main baseline characteristics of the patients
Parameters Laterally wedged
insole group
Neutrally wedged
insole group
Demographic data
Age (mean years±SD) 64±10.8 65.6±9.9
Gender (male/female) 28/54 13/61
Body mass index (mean Kg/m2±S.D.) 29±5.6 28.5±5.3
Disease duration (years±S.D.) 6±7.4 6±5.3
Symptomatic data
Steinbrocker functional class
Class I (% of patients) 7.4% 5.4%
Class II (% of patients) 59.3% 55.4%
Class III (% of patients) 33.3% 39.2%
Pain (mean mm±S.D.) 53.6±16.1 55.6±18.4
Structural data
Evaluated medial knee joint (right/left) 38/36 47/35
Joint space width of the evaluated medial knee joint (mean mm±S.D.) 2.46±1.51 2.64±1.28
Kellgren and Lawrence grade of the evaluated medial knee joint (% of patients)
Grade II 47.6% 45.9%
Grade III 36.6% 45.9%
Grade IV 15.9% 8.1%
Homolateral femoropatellar OA (% of patients) 68.4% 51.4%
Homolateral lateral femoro-tibial knee OA (% of patients) 2.7% 7.2%
Contralateral medial femoro-tibial knee OA (% of patients) 88.3% 95.7%
Contralateral femoropatellar OA (% of patients) 61.6% 47.8%
Contralateral lateral femoro-tibial knee OA (% of patients) 4.3% 5.9%Discussion
This study failed to demonstrate a relevant short-term
symptomatic effect of laterally-wedged insoles in medial
femoro-tibial OA. However, the decrease in NSAIDs con-
sumption in the treated group is in favor of a beneficial
effect of laterally-wedged insoles in the management of
peripheral medial femoro-tibial knee OA patients.
This apparent lack of effect is in contradiction with
several previous studies suggesting effectiveness of later-
ally wedged insoles in patients with medial knee OA5–7.
Three main hypotheses can be put forward to explain this
discrepancy: laterally wedged insoles are effective, but this
study failed to demonstrate it; laterally wedged insoles are
ineffective; laterally wedged insoles are effective in some
subgroups of patients rather than in the whole population.
For the hypothesis that laterally wedged insoles are
effective but that this study failed to demonstrate it, severalexplanations are possible: the control group not being a
real placebo group, concomitant therapies, compliance,
duration of follow-up, degree of wedging of the lateral
insoles.
First, the control group was not a real placebo group,
since patients wore neutrally wedged insoles that might
have relieved some symptoms through absorbing impact
loading2. Unfortunately, it was difficult to proceed differently
in the context of a prospective controlled study.
Second, during the follow-up, the patients’ usual prac-
titioners were allowed to change systemic OA therapies,
and intraarticular corticosteroid or hyaluronate injections
and joint lavage were allowed. Although the occurrence of
intraarticular injections and joint lavage were taken into
account in the analysis, they might have modified the
results. The patients used analgesics and NSAIDs when
necessary. Some improved patients might have decreased
the doses of these drugs, resulting in less improvement.
Although a more objective assessment of concomitant
medication than the self-reported NSAIDs and analgesic
intake (on a rather long period of usage) might have been
employed, and although a correction for multiple assess-
ment was not included in the statistical analysis, the results
concerning NSAIDs consumption are in favor of this
hypothesis, since there was at month 6 a statistically
significant and a clinically meaningful (−29.8%) reduction
in NSAIDs intake in the laterally wedged insole group. The
disadvantages of allowing changes in OA treatments during
the follow-up were known at the time of design of the study,
but in long term studies, it is neither ethical nor practical to
exclude all concomitant treatments9–12. However, we rec-
ognize that permitting changes in OA treatment is a caveat
and, although difficult, it might be preferable to allow no
new intervention during the follow-up in such studies.
The better compliance at month 6 observed in the
laterally-wedged insole group might also be considered aspatients), while at month 3, 130 patients wore insoles
permanently, 17 intermittently, and three no longer wore
insoles (data missing for six patients) (Table IV). At end-
point, there was a statistically significant difference
between the two groups in terms of compliance (P=0.032),
with in particular a greater frequency of patients who wore
insoles permanently in the laterally wedged insole group
than in the other group (88% vs 74%). At month 3,
compliance did not differ statistically between the groups
(P=0.12). At month 6, the reasons for no longer wearing
insoles were intolerance (one patient in the treated group,
two in the control group), inefficacy (two patients in the
treated group, one in the control group), others (one patient
in each group), and those for wearing insoles intermittently
were intolerance (three patients in the control group) and
inefficacy (three patients in the treated group, eight in the
control group) (two missing data).
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744 J. F. Maillefert et al.: Insoles in medial knee osteoarthritisTable III
Concomitant treatments with analgesics and NSAIDs at baseline and during the 6 months of the study, by
treatment groups
Parameters Laterally wedged
insole group
Neutrally wedged
insole group
Baseline
Analgesic intake during the previous 3 months (mean days±S.D.) 25.3±31 23.7±31
NSAIDs intake during the previous 3 months (mean days±S.D.) 14.1±28 15.5±24
Month 6
Analgesic intake during the previous 3 months (mean days±S.D.) 20.5±33* 22.4±32‡
NSAIDs intake during the previous 3 months (mean days±S.D.) 9.9±27† 15±28§
*P=0.11 compared to baseline (Wilcoxon’s paired-test).
†P=0.04 compared to baseline (Wilcoxon’s paired-test).
‡P=0.51 compared to baseline (Wilcoxon’s paired-test).
§P=0.56 compared to baseline (Wilcoxon’s paired-test).Table IV
Compliance by treatment groups at month 3 and 6 evaluations
Compliance Month 3 assessment Month 6 assessment
Laterally-
wedged insole
group
Neutrally-
wedged insole
group P (Chi-2)
Laterally-
wedged insole
group
Neutrally-
wedged insole
group P (Chi-square)
Permanently wearing insoles (% of patients) 84.1 82.4 87.8 74.3
Intermittently wearing insoles (% of patients) 9.8 12.2 0.12 3.7 17.6 0.032
No longer wearing insoles (% of patients) 0% 4.1 4.9 5.4
Data missing (% of patients) 6.1 1.3 3.7 2.7an indirect argument in favor of better efficacy of these
insoles. However, compliance could be related to foot
comfort and factors other than amelioration of knee OA
symptoms. Unfortunately, the high proportion of patients
wearing insoles permanently did not allow us to compare
between the groups with regard to the reasons for wearing
insoles intermittently and no longer wearing insoles.
Third, since symptoms and functional impairment can
vary with time in knee OA, and since the disease usually
progresses slowly1, the 6-month evaluation was possibly
premature.
Finally, the laterally-wedged insoles might have been
designed in an incorrect degree of wedging. In particular,
the individual modeling might have been performed accord-
ing to biomechanic evaluation during walking, rather than
according to static pedometer evaluation.
In the second hypothesis, laterally wedged insoles would
be ineffective in patients with medial knee OA. The symp-
tomatic effects have been evaluated in different studies, all
concluding to a short-term beneficial effect5–7; however,
none of these previous studies was prospective, random-
ized and controlled. The first was a comparative study
(indomethacine vs indomethacine+insoles). One group
comprised patients followed by one of the authors, and
the second group by patients followed by the other6.
Consequently, no randomization was performed, and
neither the practitioner nor the patient was blinded for
treatment groups. Moreover, the analysis was not per-
formed using an intention to treat approach. Another study
was open, with no control groups7. Finally, the main objec-
tive of the study by Ogata et al. was to evaluate the
biomechanical effects of wedged insoles on the osteoar-
thritic knee, rather than clinical efficacy; thus the study was
not double-blind randomized, and some methodological
information is lacking5. Hence the discrepancy betweenresults of our double-blind randomized study and those of
previous studies might be due to different designs, with
more convincing results from the double-blind randomized
study. In this study, the lack of significant difference
between groups in the primary and in most secondary
outcomes does not support the use of laterally-wedged
insoles in medial knee OA. Moreover, the results given in
Table II might suggest that the neutral group had a better
response in terms of WOMAC. For example, pain fell from
53.5 to 52.8 in the lateral-wedged group and from 52 to
46.4 in the neutral wedged group. The interpretation of
such results is difficult and might be only related to chance.
We would like to emphasize that there was no statistically
significant difference between the two groups concerning
these variables and that the expression of the results in
terms of responders does not support a better symptomatic
effect of neutral insoles when compared to the laterally
elevated ones.
In this study, patient’s overall assessment was a priori
chosen as the main assessment criterion. This variable is
one of the three included in the core set recommended by
OMERACT13. However, the OARSI society14 suggests
that pain, obtained using VAS, Likert scale, or WOMAC
pain subscale, should be used as primary outcome. In
this study, using the WOMAC pain subscale as primary
outcome would not have change the results or the
conclusion.
Finally, there were no arguments to support the hypoth-
esis that laterally wedged insoles are effective in some
subgroups of patients rather than in the whole population.
Particularly, although it has been suggested that laterally
wedged insoles are more effective in patients with mild or
moderate than in those with advanced structural involve-
ment5,6, there was no significant correlation between the
Osteoarthritis and Cartilage Vol. 9, No. 8 745presence of an improvement in the patient’s overall assess-
ment and the baseline Kellgren and Lawrence radiographic
stage or joint space width. Moreover, one could suppose
that laterally wedged insoles might be more effective in
patients with isolated medial femorotibial OA than in those
with medial femorotibial OA associated with another knee
compartment OA. However, an associated femoropatellar
or lateral femorotibial OA were found not to affect the
results. The only variable that was related to the presence
of an improvement in the patient’s overall assessment was
baseline overall assessment. However, the multivariate
analysis suggested that this result did not depend on
treatment groups, so it might be only due to the time-
variation of symptoms in knee OA.
Laterally wedged insoles were well tolerated by patients
with medial knee OA. Despite the lack of significant differ-
ence between groups in the primary and in most secondary
outcomes, the reduction in NSAIDs consumption might be
considered as indirect support for some efficacy of the
laterally wedged insoles. Other studies on other sets of
patients would be of interest to confirm these results. The
structural effect of laterally wedged insoles in medial knee
OA should be also evaluated.Acknowledgments
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